Full-Time

Senior Manager

Immunology

Posted on 8/22/2026

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$124.5k - $236.5k/yr

+ Long-term incentive program

Irvine, CA, USA + 2 more

More locations: Florham Park, NJ, USA | Lake County, IL, USA

Hybrid

Three days on-site and two days remotely per week.

Bachelor's, PharmD

Category
Legal & Compliance (1)

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • A Bachelor's degree in science, such as biology, chemistry, microbiology, immunology, medical technology, pharmacy, pharmacology, or nursing, plus 7 years of relevant industry experience, including regulatory affairs fellowships, Health Authority experience, or advertising and promotion experience.
  • Experience working in a complex and matrix environment.
  • Strong negotiation skills.
  • Strong oral and written communication skills.
  • Experience in United States Regulatory Affairs Advertising and Promotion.
Responsibilities
  • Capture and disseminate government, industry, and trade association activities that affect pharmaceutical regulatory policies relative to company interests.
  • Maintain awareness of pending regulatory changes, communicate their impact and relevance within Regulatory Operations, draft and finalize comments to regulators and trade associations, distribute proposed policies to subject-matter experts, and highlight key points clearly and concisely.
  • Represent the department and participate in trade associations as needed while developing working relationships with trade association managers.
  • Summarize findings in concise reports for distribution within the company.
  • Oversee the productivity and development of assigned regulatory staff responsible for ensuring that advertising and promotion materials are accurate, competitive, and compliant with internal policies, the Code of Federal Regulations, FDA guidance documents, PhRMA Guiding Principles, and the FDA and Cosmetic Act.
  • Develop and guide implementation strategies for promotional activities.
  • Apply regulatory and technical knowledge of government regulations and related skills across therapeutic areas.
  • Ensure departmental training and compliance with regulations, guidance, promotional guidelines, and standard operating procedures related to advertising and promotion for the role and direct reports.
  • Manage direct reports and assist with the development, training, and mentoring of staff members.
  • Present pertinent information effectively to appropriate cross-functional groups.
  • Deliver difficult messages to commercial organizations effectively while maintaining relationships.
  • Establish relationships with management and key stakeholders across Marketing, Medical, Clinical, Legal, Sales Training, Managed Care, and Public Affairs.
Desired Qualifications
  • A PharmD degree plus 5 years of relevant industry experience, including regulatory affairs fellowships, Health Authority experience, or advertising and promotion experience.
  • Experience in a management capacity.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to about $67.6 billion after Q2 beats.
  • FDA accepted SKYRIZI subcutaneous Crohn’s induction in April 2026; approval drives 2027 uptake.
  • AbbVie closed August 2026 financing for Apogee, extending its immunology pipeline into 2030s.

What critics are saying

  • SKYRIZI supplies nearly one-third of 2026 revenue; any setback hits AbbVie immediately.
  • Humira still fell 35.9% in Q2 2026, proving biosimilar erosion remains lethal.
  • Apogee’s $10.9 billion deal and $8 billion notes add debt before 2032 accretion.

What makes AbbVie unique

  • AbbVie dominates immunology with SKYRIZI and RINVOQ, both growing above 23% in Q2 2026.
  • AbbVie’s 2026 pipeline extends blockbuster lifecycle management through pediatric and Crohn’s expansions.
  • AbbVie generates exceptional free cash flow, financing acquisitions and dividends without operational strain.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.

Yahoo Finance
Aug 13th, 2026
Genmab raises 2026 revenue guidance to $4.5B despite epcoritamab setback; AbbVie reports $17B Q2 revenue

Genmab and AbbVie confirmed on 23 July that their jointly developed bispecific antibody epcoritamab failed to meet its primary endpoint in a Phase 3 trial. The study evaluated epcoritamab monotherapy against chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. In the US, where overall survival was the sole primary endpoint, the trial did not demonstrate statistically significant improvement. Despite the setback, epcoritamab maintains its accelerated FDA approval. Both companies will review the full data set with regulators to determine next steps. Genmab reported H1 2026 revenue of $2.051 billion, up 25% year-over-year, raising full-year guidance to $4.325–$4.525 billion. AbbVie posted Q2 2026 net revenues of $16.99 billion, up 10.2%, driven by its immunology portfolio generating $8.79 billion.

Yahoo Finance
Aug 12th, 2026
AbbVie delivers 10.4% revenue growth and 34% margin but stock lags peers despite strong fundamentals

AbbVie's strong operational performance has not translated into stock gains matching its pharmaceutical peers. The drugmaker achieved 10.4% revenue growth and a 34% operating margin over the past year, ranking second among six key competitors. Despite these results, AbbVie's stock returned 30% over twelve months, trailing Merck's 67% and Johnson & Johnson's 54%. The disconnect appears rooted in market concerns about future competition. Analysts questioned management about competitive dynamics for key immunology drugs SKYRIZI and RINVOQ, which each grew sales 24%. The company trades at 70.1 times earnings but lacks the premium stock performance of peers. The market seems to be pricing in risks that AbbVie's high-performing drugs will face tougher competition, potentially eroding current growth rates and margins.

Manufacturing Digital
Aug 12th, 2026
Why Bristol Myers Squibb is investing $2.3bn in Texas.

Why Bristol Myers Squibb is investing $2.3bn in Texas. August 12, 2026 Bristol Myers Squibb is investing US$2.3bn in a new manufacturing facility in Houston, Texas, aiming to reinforce the US's pharmaceutical supply chain Bristol Myers Squibb (BMS) says it will invest US$2.3bn into a new manufacturing hub in Houston, Texas to boost its domestic pharmaceutical supply chain. The plan is part of the company's five year commitment to invest US$40bn in the US across research and development, domestic manufacturing and technology. Christopher Boerner, CEO of BMS, says: "As part of our US$40bn commitment to the United States, we're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs." What will the investment create? BMS says its new hub will allow the company to manufacture multiple types of medicine including small molecules, biologics and antibody drug conjugates. The campus will be located at Generation Park, spanning across 600,000 square feet, and aims to initially create around 500 skilled jobs. Building this new facility will allow the company to manufacture multiple types of medicine including small molecules, biologics and antibody drug conjugates. Initial plans are expected to bring construction between 2027 and 2030, during which BMS is expecting to create around 2,000 construction and other indirect jobs. BMS currently has seven manufacturing and commercial manufacturing facilities across the world. US pharmaceutical supply chain. According to research from the US Pharmacopeia in 2024, more than 50% of active pharmaceutical ingredient (API) production comes from Europe and India, while the US accounts for just 12%. The new BMS facility is expected to lower reliance on overseas production and develop the US supply chain. US Secretary of Commerce Howard Lutnick says: "Bristol Myers Squibb's US$2.3bn investment in Texas will create hundreds of high-paying jobs and strengthen our pharmaceutical supply chains, ensuring America is never reliant on foreign sources for critical medicines." In January 2026, Abbvie committed US$100bn towards domestic research, development and capital investments over a 10 year period. This funding has already seen some allocations, including across two API plants in Illinois, and another US$1.4bn for a manufacturing campus focusing on immunology, neuroscience and oncology products in North Carolina. Abbvie has also acquired a manufacturing facility in Arizona, where it designated US$175m to expand capacity for drug delivery devices. Company Portals